Pfizer (PFE) Q1 2026 earnings review
Top-Line Growth Returns, But Profits Contract Amid LOE Cliff
Pfizer finally broke its streak of COVID-induced revenue declines, posting a 5% YoY revenue increase (2% operational). The underlying non-COVID business is healthy, with recently launched and acquired products surging 22% operationally. However, this top-line success completely bypassed the bottom line. Adjusted EPS decelerated sharply, falling 18% YoY to $0.75 as cost of sales spiked and R&D spending increased. With a looming $1.5B loss of exclusivity (LOE) cliff in 2026, management's narrative of 'operational efficiency' is contradicted by significant margin compression in the current quarter.
🐂 Bull Case
The Seagen and Biohaven deals are paying off. Launched and acquired products grew 22% operationally, led by Padcev (+39%) and Nurtec (+41%), proving Pfizer can execute on integrated assets.
While Comirnaty (-59%) and Paxlovid (-63%) are still declining, their base is now small enough that strong non-COVID operational growth (+7%) can finally push total company revenues into positive territory.
🐻 Bear Case
Despite a massive multi-year cost realignment program targeting $7.7B in savings by 2027, Adjusted Cost of Sales jumped 31% YoY. Adjusted EPS falling 18% on positive revenue growth indicates severe negative operating leverage.
The Vyndaqel family, a critical growth engine, decelerated to just 4% operational growth in Q1 (down from 33% a year ago), largely due to U.S. net price erosion from new payer contracts. With a 2028 patent cliff approaching, this early plateau is highly concerning.
⚖️ Verdict: ⚪
Neutral. Pfizer is successfully pivoting its revenue base away from COVID via strong acquired product growth. However, severe margin compression and impending patent cliffs make the near-term earnings profile highly unattractive.
Key Themes
Oncology and Acquired Products Accelerating
Pfizer's heavy M&A investments are actively bridging the LOE gap. Padcev surged 39% operationally, driven by first-line urothelial cancer market share. Oncology biosimilars accelerated 52%, and Nurtec ODT jumped 41%. In aggregate, launched and acquired products grew 22% operationally, validating the commercial integration of Seagen and Biohaven assets.
Margin Collapse Contradicts Efficiency Narrative
Management highlighted an 'ongoing focus on operational efficiency,' yet the data shows Reversing profitability. Adjusted Cost of Sales jumped 31% (driven by unfavorable FX and non-recurrence of royalty benefits), crushing the adjusted gross margin. Simultaneously, Adjusted R&D rose 12% to fund obesity and oncology trials. The result: an 18% collapse in Adjusted Net Income.
Vyndaqel Growth Decelerating Sharply
The Vyndaqel family is one of Pfizer's most important organic growth pillars, but growth is Decelerating rapidly. After posting 33% operational growth in 25Q1, it fell to just 4% in 26Q1. Management blamed U.S. net price erosion from new payer contracts. With the patent cliff approaching in 2028, early signs of pricing pressure cap the drug's peak potential.
R&D Pipeline Deepening in Key Mega-Markets
Pfizer is aggressively funding its future, aiming for 20 pivotal study starts in 2026. Specific product innovation includes positive Phase 2 data for atirmociclib (a potential first-in-class CDK4 inhibitor for breast cancer) showing significant progression-free survival, and advancing Phase 3 plans for tilrekimig (trispecific antibody for atopic dermatitis).
TrumpRx.gov and the U.S. Pricing Macro-Environment
On the macro front, Pfizer formally launched its participation on TrumpRx.gov, providing discounts on 30+ medicines. This is tied to the broader Most Favored Nation (MFN) agreement with the U.S. government. While positioned as strengthening U.S. leadership, the mandatory discounting mechanisms are structurally deflationary for domestic pharmaceutical pricing moving forward.
Other KPIs
Reversing trend. Cost of sales jumped to 24.6% of revenues from 20.7% a year ago. This 25% YoY absolute increase was a primary culprit for the earnings miss, completely offsetting the 5% revenue gain.
Pfizer completed the exit of its 11.7% stake in ViiV, netting ~$1.65B in cash after taxes. This provides crucial dry powder to delever the balance sheet, which has been stretched by the Seagen and Metsera acquisitions.
Decelerating. COVID revenues continue their structural decline. However, because they now make up a much smaller percentage of total sales, the core business (+7% operational growth) is finally capable of dragging the top line upward.
Guidance
Stable. Reaffirmed guidance implies a slight YoY decline at the midpoint ($61.0B vs 2025 actual of $62.5B). This bakes in an anticipated $1.5 billion headwind from recent and expected generic/biosimilar competition (LOE cliff).
Decelerating. The reaffirmed midpoint of $2.90 implies roughly a 10% decline from FY25's $3.22. It reflects the ongoing margin pressures seen in Q1, higher R&D investments ($10.5-$11.5B), and the LOE cliff.
Key Questions
Visibility into Margin Recovery
With Adjusted Cost of Sales spiking and effectively wiping out your revenue beat this quarter, what gives you confidence that your $7.7B cost realignment program will actually drop to the bottom line in H2 2026 rather than just offsetting inflation and R&D costs?
Vyndaqel Pricing Power
U.S. Vyndaqel revenues were dragged down by new payer contracts. Is this level of net price erosion a new baseline, and how does this alter the peak revenue assumptions ahead of the 2028 LOE?
TrumpRx.gov Margin Impact
You highlighted your participation in TrumpRx.gov offering 'significant discounts' on 30+ medicines. How much of the Q1 U.S. pricing pressure is directly attributable to this agreement, and is the full-year margin impact fully baked into the $2.80-$3.00 EPS guide?